Skip to main content

Table 2 Baseline demographic and disease characteristics (overall population)

From: Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data

Characteristica

PBO

(n = 646)

CANA 100 mg

(n = 833)

CANA 300 mg

(n = 834)

Sex, n (%)

 Male

334 (52)

408 (49)

404 (48)

 Female

312 (48)

425 (51)

430 (52)

Age, years

56.3 (9.8)

55.9 (10.1)

55.7 (9.5)

Race, n (%)

 White

470 (73)

591 (71)

610 (73)

 Black or African American

28 (4)

43 (5)

48 (6)

 Asian

82 (13)

103 (12)

100 (12)

 Otherb

66 (10)

96 (12)

76 (9)

HbA1c, %

8.0 (0.9)

8.0 (0.9)

8.0 (1.0)

Body weight, kg

89.3 (21.7)

89.8 (22.3)

88.5 (22.0)

Systolic BP, mmHg

128.2 (13.3)

128.0 (12.8)

128.8 (12.8)

eGFR, mL/min/1.73 m2

87.0 (19.8)

88.3 (19.0)

88.8 (18.9)

Duration of T2DM, years

7.5 (6.2)

7.2 (5.8)

7.4 (6.2)

  1. Data have been previously reported [19, 22, 24]
  2. PBO placebo, CANA canagliflozin, BP blood pressure, eGFR estimated glomerular filtration rate, T2DM type 2 diabetes mellitus, SD standard deviation
  3. aData are mean (SD) unless otherwise indicated
  4. bIncludes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other, unknown, and not reported
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840